Review Article

Novel RNA Markers in Prostate Cancer: Functional Considerations and Clinical Translation

Julia M. A. Pickl, Doreen Heckmann, Leonie Ratz, Sabine M. Klauck, and Holger Sültmann

Working Group Cancer Genome Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

Correspondence should be addressed to Holger Sültmann; h.sueltmann@dkfz.de

Received 7 March 2014; Revised 1 August 2014; Accepted 5 August 2014; Published 28 August 2014

Academic Editor: Andreas Doll

The availability of ultra-high throughput DNA and RNA sequencing technologies in recent years has led to the identification of numerous novel transcripts, whose functions are unknown as yet. Evidence is accumulating that many of these molecules are deregulated in diseases, including prostate cancer, and potentially represent novel targets for diagnosis and therapy. In particular, functional genomic analysis of microRNA (miRNA) and long noncoding RNA (lncRNA) in cancer is likely to contribute insights into tumor development. Here, we compile recent efforts to catalog differential expression of miRNA and lncRNA in prostate cancer and to understand RNA function in tumor progression. We further highlight technologies for molecular characterization of noncoding RNAs and provide an overview of current activities to exploit them for the diagnosis and therapy of this complex tumor.

1. Introduction

Prostate cancer (PCa) is the most frequent tumor in men and a major cause of cancer-related morbidity and mortality. The diagnostic application of the prostate specific antigen (PSA) has led to widespread overdiagnosis and subsequent overtreatment of clinically insignificant tumors. This problem will extensively aggravate in the future: with rising life time expectancy, the number of men diagnosed with PCa will increase since the frequency of PCa is steeply rising in elderly men. Thus, there is a huge demand for novel markers for improved PCa diagnosis, prognosis, and therapy decision.

Facilitated by the implementation of ultra-high throughput sequencing technologies, the recent discoveries of the ENCODE consortium (http://encodeproject.org/ENCODE/) confirmed that 80% of the human genome is transcribed [1–4]. The GENCODE effort has provided the annotation of more than 9000 IncRNAs [5], as well as micro- (mi-), small nucleolar (sno) RNA, piwi-interacting (pi) RNA, and others. In parallel, the number of investigations covering the functional analysis of these molecules has increased substantially. Based on these data, it is becoming obvious that many noncoding RNAs are involved in the regulation of gene expression in health and disease, including cancer (Figure 1). For example, global analyses of miRNA expression in cancers revealed robust signatures differentiating between malignant and benign tissues [6], between tumors of several origins, and between primary tumors and metastases [7]. The characterization of miRNA and IncRNA involvement in PCa is likely to result in a better understanding of tumor progression and the identification of novel therapy targets. Here, we provide a summary of recent progress in analyzing noncoding RNA in PCa and in attempting to advance miRNAs and IncRNAs into diagnostic and therapeutic markers.

2. miRNA in Prostate Cancer

MiRNAs are ~20–22 nt short noncoding RNAs, which regulate gene expression at the posttranscriptional level by mRNA repression and/or degradation. MiRNAs are transcribed as pri-miRNAs by RNA polymerase II (RNA Pol II) and processed by the RNase III enzyme Drosha to generate precursor miRNAs (pre-miRNAs; Figure 1) [8]. Dicer, another RNase III enzyme, then cleaves the pre-miRNA into ~20–22 long RNA duplexes. Subsequently, the strand with the stable
5’ end is removed, whereas the complementary strand with the less stable 5’ end is incorporated into Argonaute (AGO) proteins to form the RNA induced silencing complex (RISC). MiRNAs guide the RISC to target mRNAs via sequence complementarity [8–11].

Many miRNAs are known to be deregulated in cancer [6]. For instance, miRNAs are differentially expressed between benign prostate and PCa tissues: in a genomewide microarray-based microRNA expression study, 25 miRNAs were found to be deregulated [12]. Here, miR-375 and miR-200c showed highest upregulation in PCa tumor tissue, whereas miR-221 and miR-222 were the most downregulated miRNAs [12]. Using a sequencing-based approach, the same group identified 33 miRNAs being up- or downregulated >1.5-fold in PCa tissue [13]. Here, miR-143 and miR-145 were the highest downregulated ones in PCa [13]. Consistent with these data, an independent study found miR-145, miR-221, and miR-222 among the five most significantly downregulated miRNAs [14], and we identified miR-375 and miR-141 as significantly upregulated in PCa tissue [15].

Other analyses revealed the association of miRNA expression with distinct PCa: for instance, miR-375 expression was reported to be dependent on pT and pN status (TNM staging system) of PCa patients, with the highest enrichment in pNI tumors [16]. Moreover, ten miRNAs (including miR-145, miR-221, and miR-222) were downregulated and five (including miR-375 and miR-96) upregulated in advanced PCa, whereas miR-96 was associated with tumor recurrence after radical prostatectomy [17]. MiRNAs are also known to correlate with Gleason score: in high-grade PCa, increased expression of miR-31, miR-182, and miR-205 was identified when compared to intermediate-grade PCa [18].

The functional consequences of differential expression of various miRNAs have been studied in vitro by many groups. Here, we can address only the most prominent examples: miR-375 was found upregulated in several PCa studies and was known to target Sec23 homolog A (SEC23A) [19], which was involved in trafficking from ER to Golgi [20]. The authors suggested that miR-375-mediated SEC23A downregulation impairs cellular immunogenicity of PCa by reducing HLA class I cell surface receptors [19]. MiR-375 was also shown to downregulate the phosphatase PHLPP2 and to strongly increase prostate carcinoma cell growth [16]. MiR-141, which is upregulated in PCa tissue, was found to downregulate the gene coding for the nuclear receptor subfamily 0, group B, member 2 (NR0B2) in prostate epithelial cells. In this way, miR-141 prevented the inhibitory effects of NR0B2 on androgen receptor (AR)-regulated genes [21]. In contrast, miR-143 and miR-145 were found to be downregulated in PCa tissue and to be involved in PCa development via regulation of myosin VI (MYO6) [13]. MYO6 was involved in cancer cell dissemination and described as a potential PCa marker [22, 23].
Interestingly, miRNAs, which have not been described as highly deregulated in Pca tissues, were also found to play crucial roles in prostate carcinogenesis. For instance, miR-200b attenuated Pca cell growth and invasiveness [24, 25]. Studies in the Pca cell line PC-3 suggested that miR-200b mediates the reversal of the epithelial-to-mesenchymal transition (EMT) by targeting the promotastatic transcription factors Zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) [25]. Overexpression of miR-200b led to increased levels of the epithelial markers E-cadherin, cytokeratins 8 and 18, as well as downregulation of the mesenchymal markers fibronectin and vimentin [25, 26]. Another study found miR-1 to be reduced with Pca progression. Slug is a regulator of mesenchymal differentiation and was assumed to repress miR-1 and miR-200 transcription whereas miR-1 and miR-200 are also able to regulate Slug by a mutually inhibitory feedforward loop [27]. Moreover, miR-1 was found to act as a mediator of oncogenic pathways in the Pca cell lines PC-3 and LNCPaP; the heat-shock protein HSPBI reduced miR-1 levels leading to an activation of AR and TGFB1 signaling cascades [28].

MiRNAs are also able to regulate the expression of important epigenetic marker genes. For instance, miR-34b targeted methyltransferases and deacetylases in Pca [29]. MiR-34b is also an example for epigenetic miRNA regulation via a positive feedback loop. MiR-34b was found to directly target the AKT pathway like AKT itself and its downstream genes GSK3B, CTNNB1, MYC, and CCND1, which were involved in cell proliferation and survival [29]. In a Pca xenograft model, miR-34b exhibited antitumor properties by decreasing prostate tumor growth [29]. This was probably due to affecting EMT since miR-34b expression decreased the mesenchymal markers vimentin, ZO1, N-cadherin, and SNAIL, and increased E-cadherin [29]. Furthermore, miR-152 was reported to downregulate DNA (cytosine-5)-methyltransferase 1 (DNMT1) in LNCPaP, PC-3, and MDA-Pca-2b cells. DNMT1 siRNA caused an increase of miR-152 expression, suggesting a reciprocal relationship between DNMT1 and miR-152. Increased DNMT1 and depletion of miR-152 were assumed to arise during the progression to advanced Pca [30]. The miR-200 family was downregulated by the histone methyltransferase enhancer of zeste homolog 2 (EZH2) [24]. EZH2 is a component of the polycomb repressive complex 2 (PRC2), which is involved in epigenetic regulation of cell homeostasis. EZH2 expression was elevated in aggressive forms of Pca [31]. MiR-200 family on the other hand represses PRC1 proteins BMI1 and RING2. Therefore, increased PRC2 levels lead to an increase of PRC1 expression due to miRNA linkage, suggesting crucial roles for miRNA in regulating the epigenetic silencing machinery [24].

MiRNAs are primarily known as key regulators of active genes. However, it has recently been shown that the expression of the PTEN pseudogene (PTENP1) is able to rescue the expression levels of its ancestral gene PTEN by competing for the same set of miRNAs (miR-20a, miR-19b, miR-21, miR-26a, and miR-214) [32]. Similarly, the pseudogene KRASP1 depressed KRAS in DU145 cells, probably by sharing common sites for miR-143 and let-7 [32]. Thus, expressed pseudogenes can display tumor suppressive or oncogenic properties by acting as competitive endogenous RNAs (ceRNAs) for their corresponding active genes: the increased number of miRNA binding sites upon pseudogene expression was able to titrate the pool of available miRNAs in Pca cells, and miRNA concentrations are regulated by the abundances of their target genes. In this concept, target RNAs are not only passive substrates of miRNAs but also active players in the regulatory networks leading to Pca progression.

The identification of their target genes is essential to estimate the potential of miRNAs as biomarkers. Many bioinformatic tools are able to predict miRNA target genes (Table 1). However, since these tools are based on certain assumptions (e.g., base complementarity in the 3' UTR, thermodynamic stability, target-site accessibility, and evolutionary conservation of miRNA binding sites), their predictions are accompanied by large numbers of false positives. Thus, experimental approaches for targetome identification in vitro are required. For example, using AGO-RNA immunoprecipitation, followed by sequencing (AGO-RIP-Seq) AGO2/miRNA/RNA target complexes are captured from cells stably expressing a miRNA of interest. MiRNA-associated targets are then identified and quantified by deep transcriptome sequencing. AGO-RIP-Seq also enables the identification of novel nonannotated RNA targets like IncRNAs or pseudogenes. Other methods (AGO-HITS-CLIP [33, 34], AGO-PAR-CLIP [35], and CLASH [36]) use crosslinking of the AGO complex to obtain more information about miRNA binding to target genes. These techniques have revealed that some miRNAs can also bind their targets in the coding regions of genes and that other miRNAs do not require base complementarity at all in order to regulate target gene expression [33–36]. These methods are rather novel, and systematic studies reporting the experimental analysis of genomewide miRNA targetomes in Pca have not been described to the best of our knowledge.

MiRNAs are also known to be present in the nucleus [37–40]. Nuclear miRNAs are considered as regulators of gene expression at the transcriptional level (reviewed in [41]). For instance, miRNAs are supposed to bind to promoter sequences in an AGO-dependent manner to regulate gene transcription in the Pca cell line PC-3. This hypothesis was supported by the finding that AGO1-bound promoter sequences contain putative miRNA binding sites [39] and suggest a role for miRNAs in Pca not only in the cytoplasm, but also in the nucleus.

3. Long Noncoding RNA in Prostate Cancer

Long noncoding RNAs (lncRNAs) are defined by their length, which ranges from 200 bases up to 100 kb. LncRNAs have adopted the transcriptional machinery from protein-coding genes (Figure 1): they are primarily transcribed by RNA Pol II, frequently contain a 5' terminal methylguanosine cap, and are often spliced and polyadenylated [42]. However, a set of nonpolyadenylated lncRNAs has also been identified to be transcribed from RNA polymerase III promoters [43, 44]. The fact that lncRNAs have been found to bind to ribosomes raises the possibility that they are potentially translatable into proteins. Indeed, ribosome profiling [45]
| Database name           | Description                                                                 | URL                                                      |
|------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------|
| **miRNA**              |                                                                             |                                                          |
| TargetScan             | miRNA target prediction based on sequence complementarity                   | http://www.targetscan.org/                               |
| PITA                   | miRNA target prediction based on target site accessibility                   | http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html   |
| MiRecords              | Collection of miRNA target prediction programs                              | http://mirecords.biolead.org/                            |
| MicroPIR               | Prediction of miRNA-promoter interactions Identification of miRNAs responsible for coregulated gene expression patterns discovered through transcriptome profiling | http://www4a.biotec.or.th/micropir/                      |
| miRvestigator          | Identification of miRNAs responsible for coregulated gene expression patterns discovered through transcriptome profiling | http://mirvestigator-web-application-identify-mirnas-responsible-co-regulated-gene-expression/mirvestigator-web-application-identify-mirnas-responsible-co-regulated-gene-expression/    |
| DIANA miRPath v.2.0    | Combinatorial effect of microRNAs in pathways                               | http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/index |
| miRGator v.2.0         | Integrated system for functional investigation of microRNAs                 | http://mirgator.kobic.re.kr/                              |
| mirConnX               | Condition-specific mRNA-microRNA network integrator                         | http://mirconnx.csb.pitt.edu/job_config                   |
| MAGIA                  | Tool for miRNA and genes integrated analysis                                 | http://gencomp.bio.unipd.it/magia/start/                 |
| **IncRNA**             |                                                                             |                                                          |
| ChIPBase               | Platform decoding transcription factor binding maps, expression profiles, and transcriptional regulation of ncRNAs from ChIP-Seq data | http://deepbase.sysu.edu.cn/chipbase/                     |
| DIANA-LncBase          | Computationally predicted miRNA targets on IncRNAs                           | http://www.microrna.gr/LncBase                           |
| IncRNome               | Biologically oriented knowledge base for IncRNAs in humans                  | http://genome.igib.res.in/IncRNome                       |
| starBase v.2.0         | RNA interaction networks based on CLIP-Seq data                              | http://starbase.sysu.edu.cn/                             |
| NONCODE v.3.0          | Expression and functional IncRNA data obtained from reannotated microarray studies | http://www.noncode.org                                  |
| IncRNAdb               | Database of annotated eukaryotic IncRNAs                                    | http://www.lncrnadb.org                                  |
| LncRNA Disease database| IncRNAs associated with a number of diseases                               | http://www.cuilab.cn/lncrnadisease                        |
| Functional IncRNA Database| Mammalian long non-protein-coding transcripts that have been experimentally shown to be both noncoding and functional | http://www.valadkhanlab.org/database/                     |
| LNCipedia 2.0          | Database for annotated human IncRNA transcript sequences and structures     | http://www.lncipedia.org                                 |
| ncRNA Expression Database (NRED) | Integration tool for annotated expression data of ncRNAs from mouse and human | http://jsm-research.imb.uq.edu.au/nred/cgi-bin/ncrnadb.pl |
| circBase               | Database of circular RNAs                                                   | http://www.circbase.org                                  |
| Linc2GO                | Functional annotation of human lncRNA based on the ceRNA hypothesis         | http://www.bioinfo.tsinghua.edu.cn/~liuke/Linc2GO/index.html |
| ceRNA-Competing Endogenous mRNA Database/CEFINDER | Web-server for identification of ceRNA for a given mRNA target based on the homology of miRNA binding sites present in the 3' UTR sequence | http://www.oncomir.umn.edu/cefinder/                      |
and mass spectrometry approaches [46] detected small peptides potentially derived from lncRNAs. However, the lack of conserved open reading frames supports the idea that lncRNAs do not encode proteins but rather exert regulatory functions. LncRNAs are cataloged according to their genomic localization: long intergenic noncoding RNAs (lincRNAs) are derived from regions that are devoid of other genes, whereas intronic lncRNAs are transcribed from introns of protein coding genes. LncRNAs originating from opposite strands of the same genomic locus are called sense/antisense pairs and are divided into convergent (head-to-head), divergent (tail-to-tail), and fully overlapping transcripts [47]. LncRNAs are expressed at much lower levels and with much higher cell-type specificity than mRNAs [5]. Although lncRNAs are observed in many species, their degrees of evolutionary conservation are low, and some of the human lncRNAs are thought to have arisen solely in primates [5].

In PCa, the most prominent and clinically relevant RNA biomarker is the antisense lncRNA PCA3, which is overexpressed in >95% of primary tumors [48]. PCA3 is a diagnostic biomarker detectable in urine [49], with higher specificity compared to PSA [50]. One of the first lncRNAs suggested as a marker for PCa incidence, androgen-dependent proliferation, and antiapoptotic signaling in cell lines was the PCA gene expression marker 1 (PCGEM1) [51–54]. Overexpression of PCGEM1 in tumor cells inhibited PARP (poly-ADP-ribosepolymerase) cleavage and delayed the induction of p53 and p21 [52], resulting in increased chemoresistance. PCGEM1 was found to bind to AR at methylated K349 and to regulate the expression of AR target genes, which stimulated tumor growth in a PCa xenograft mouse model [54]. Additionally, two single-nucleotide polymorphisms (SNP) contributing to cancer risk were identified in PCGEM1 [55].

In a more recent and comprehensive study, Prensner and colleagues, by analyzing the transcriptomes of 102 prostate tumors and cell lines using next generation sequencing [56], identified 121 so far nonannotated PCA-associated noncoding RNA transcripts (PCATs). PCAT-1 was upregulated in a subset of metastatic and high-grade localized prostate tumors. PCAT-1, a transcriptional target of EZH2, stimulated cell proliferation [56] and impaired homologous recombination by repressing of the BRCA2 gene [57]. PCA noncoding RNA 1 (PRNCR1; PCAT-8), which is located immediately adjacent to PCAT-1 and the c-MYC oncogene at the well-known PCa risk locus on chromosome 8q24 [58, 59], was identified to be upregulated in aggressive prostate tumors [54]. PRNCR1-bound DOT1-like histone H3K79 methyltransferase (DOT1L) methylated the AR at position K349, which mediated the interaction of AR with PCGEM1, thereby resulting in ligand-independent activation of AR signaling and cell proliferation [54]. PCAT-18 was recently suggested as a biomarker for metastatic PCa [60]. Knockdown of PCAT-18 decreased cell proliferation, migration, and invasion but also triggered apoptosis by promoting caspase activity [60]. In another study, PCAT-114 (SCHLAP1) expression correlated with high-grade, metastatic PCa (see below). By analyzing the transcriptomes of 14 prostate tumors and adjacent benign tissues in another genomewide approach, 137 new lncRNAs were identified [61]. One of these, the metastasis associated in lung adenocarcinoma transcript 1 (MALAT-1), was suggested to be a novel marker for PCa diagnosis [62]: high expression of MALAT-1 correlated with high Gleason score, PSA, tumor stage, and castration-resistant PCa (CRPC).

The majority of PCa are driven by androgen signaling. Various studies have highlighted the functions of androgen-responsive or AR-interacting lncRNAs: Takayama and colleagues identified the antisense lncRNA C-terminal binding protein (CTBPI-AS) as highly upregulated in PCa, by repressing its sense gene CTBPI, an AR corepressor. This is achieved by recruitment of the transcriptional repressor SFPIQ (splicing factor proline/glutamine-rich) and histone deacetylases to the promoter of CTBPI [63], thereby promoting androgen-dependent and castration-resistant tumor growth [63]. The PCa-upregulated lncRNA PlncRNA-1 modulates apoptosis and proliferation through regulation of the AR [64]. Recently, PCAT-29 was identified as an androgen-repressed suppressor of growth and metastases of prostate tumors [65]. The same group contradicted the prognostic value of PCGEM1 and PRNCR1 in aggressive PCa [54]: in a large high-risk PCa patient cohort, Prensner and colleagues could not find any evidence for the binding of these lncRNAs to the AR [66].

As lncRNAs do not encode proteins, their functions are closely associated with their abundance. Bioinformatic tools such as the “guilt by association analysis” [67] are capable of predicting the function of an lncRNA. This method uses coexpression analysis of lncRNAs with protein coding genes in signaling pathways to predict the functions of the lncRNAs. This approach has led to the prediction of various roles for lncRNAs, ranging from stem cell pluripotency to cancer [42]. Besides such bioinformatic approaches and databases listing annotated lncRNAs and functional assignment (Table 1), several crosslinking methodologies have been developed to experimentally elucidate the interactomes of lncRNAs in vitro. Chromatin isolation with RNA purification (ChIRP) [68] and capture analysis of RNA targets (CHART) [69] are able to copurify lncRNA-bound proteins and DNA in juxtaposition. In DHT- (dihydrotestosterone-) stimulated LNCaP PCa cells, ChIRP uncovered thousands of PCGEM1 occupancy sites, colocalizing with ARE and H3K4me1-marked enhancers [54].

The regulatory potential of lncRNAs, in particular lincRNAs, has been best characterized in the context of their roles as epigenetic modulators. It was observed that 20% of cellular lncRNAs are associated with specific chromatin modification complexes, such as PR2C, which mediates histone H3 lysine 27 trimethylation (H3K27me3) [70, 71]. ANRIL, an lncRNA overexpressed in PCa, mediated epigenetic silencing of the adjacent tumor suppressor p15 via H3K27 methylation of the CDKN2A (INK4a/ARF) locus by directly interacting with SUZ12, a component of PR2C, and CBX7, a PRC1-associated chromodomain-containing protein [72, 73]. In aggressive PCa, aberrantly high expression of PCAT-114 inhibited SWI/SNF-mediated epigenetic regulation, due to direct disruption of SNF5 activity, a core unit of the SWI/SNF complex [74]. As it has been shown that the expression of PCA-associated lncRNAs can be regulated by long terminal repeats (LTRs) [75], PCAT-114 might be regulated through an LTR in its 5′ UTR (own unpublished observations).
Currently, there is little evidence for a direct interaction between lncRNA and DNA [68]. In contrast, the crosstalk of lncRNA with other RNA species has been studied in detail [35, 76]. Antisense lncRNAs can regulate the stability and translation of complementary mRNAs. For example, translation of the UCHL1 mRNA was found to be regulated by its antisense lncRNA through complementary 5′ overlap and an embedded inverted SINEB2 element [77]. In another example, imperfect base pairing between Alu elements in lncRNAs and the 3′ UTR of translationally active mRNAs resulted in a double-stranded RNA, which is bound by staufen double-stranded RNA binding protein I (STAU1) and subsequently targeted for degradation [78].

The ceRNA concept [32] also suggests that lncRNAs—like miRNAs—act as natural sponges (Figure 1). In this context, a long noncoding circular RNA (circRNA) was identified to harbor more than 70 target sites for miR-7. Binding of this miRNA to the sponge circRNA suppressed miRNA activity, resulting in miRNA target derepression [79, 80]. CircRNA datasets are publically available via http://www.circbase.org/ (Table 1).

The noncoding part of the human genome offers comprehensive prospects to identify the genetic factors and mechanisms, which are critical for PCa initiation, development, and progression. However, a recent study suggests that a particular lncRNA may exert both oncogenic and tumor-suppressive functions in PCa [81]. This indicates that lncRNA action is highly context-dependent, and further efforts are required to understand the increasing complexity of lncRNA function in health and disease.

4. PCa Diagnosis and Treatment Monitoring Using Circulating RNA Markers

The remarkable stability of noncoding RNAs prompted efforts to evaluate their potential as diagnostic or prognostic molecular markers. In particular, genetic material released from tumor cells into the blood or other body fluids (“liquid biopsy”) could provide a rich source of such markers that can be exploited to gain insights into the molecular alterations associated with disease progression [82]. In PCa, liquid biopsies could be highly valuable since the heterogeneity of the tumors often precludes precise staging and grading. In addition, a faithful representation of tumor aggressiveness in easily accessible liquids could lead to an improved therapy decision.

miRNAs circulating freely in blood have been studied as potential biomarkers for PCa [83, 84]. Several miRNAs were demonstrated to discriminate between PCa and healthy controls or patients with benign prostate hyperplasia (BPH) [83, 85], as well as between localized and metastatic PCa [86]. Brase et al. observed an overall higher level of circulating miRNAs in serum samples of patients with advanced PCa compared to those with primary PCa [15]. Of 667 miRNAs screened, 69 miRNAs were found to be more abundant in sera of lymph-node positive versus negative PCa patients. MiR-375 and miR-141 showed statistically significant correlation with clinical patient parameters and were identified as the best serum markers for aggressive PCa [15]. Significantly higher abundance of miR-141 in localized PCa compared to metastatic disease in plasma samples was also seen by other groups [87, 88], while miR-21 distinguished best between early-stage disease and healthy controls and was correlated with resistance to docetaxel [89]. Serum miR-194 correlated with biochemical recurrence and poor prognosis [88]. The first clinical studies are ongoing which examine the benefit of circulating miRNAs for PCa diagnosis and disease monitoring (Table 2). These include investigations to determine whether specific miRNA profiles are related to PCa outcome in high-risk PCa patients as well as screening studies for novel markers (including miRNA and lncRNA) associated with tumor progression in general (e.g., http://www.mdanderson.org/) or with locally recurrent or metastatic PCa. Furthermore, the potential of circulating miRNA markers as tools for companion diagnostics in clinical trials (prediction of therapy response against abiraterone or combination therapies; Table 2) is currently being explored.

Two recent studies suggested the detection of transcript levels of selected mRNAs in whole-blood samples of patients with CRPC as useful prognostic markers [90, 91]: a panel consisting of six circulating mRNA markers (ABL2, CIQA, SEMA4D, TIMP1, ITGAL, and CDKN1A) predicted survival when compared to clinical and histopathological parameters of prognostic significance in CRPC [91]. Poor prognosis and poor overall survival of patients with CRPC were correlated with a nine-gene model (RHAG, C4A1, HEPACAM2, SNCA, HEMGN, SOX6, TMEM56, OSBP2, and RHD) [90]. The determination of PCA3 in peripheral blood in combination with increased PSA level (>10ng/mL) showed high specificity and improved diagnostic accuracy to distinguish BPH from PCa [92]. Since PCa often carries genomic rearrangements involving androgen-regulated genes, the role of rearrangement-associated biomarkers could also be exploited for diagnostic purposes. Urine-based combined detection of PCA3 and TMPRSS2:ERG DNA was used for improved risk stratification of men with elevated serum PSA levels to guide further disease management [93], and changes in PCA3 and TMPRSS2:ERG levels are currently used as marker to evaluate the effect of treatment with the gonadotropin-releasing hormone agonist Triptorelin (Decapeptyl) in a Phase III multicenter study in patients with advanced PCa (NCT01020448; https://clinicaltrials.gov/). A multiplex marker panel consisting of PCA3, TMPRSS2:ERG, annexin A3, sarcosine, and serum PSA showed improved diagnostic accuracy for PCa [94].

Circulating miRNAs have been found to be present in microvesicles such as exosomes (Figure 1). Exosomes are nanosized (40–100 nm) extracellular vesicles secreted from cells via the endosomal pathway. Tumor cells release exosomes at increased levels, which are then detectable in different body fluids. Exosomal miRNAs reflect the miRNA signature of the tumor, and differences in miRNA content and expression were found in exosomes derived from cancerous versus noncancerous cell lines and in tumor-derived exosomes compared to those from healthy individuals [95–97]: in PC-3 cell lines, miRNA profiling identified 31 miRNAs that were
Table 2: MiRNA-based biomarker studies in prostate cancer.

| Trial title | Objectives | Study type | Source | Trial number |
|-------------|------------|------------|--------|--------------|
| Micro-RNA Expression Profiles in High Risk Prostate Cancer | Correlation of miRNA expression with prostate cancer outcome | Observational retrospective | Radical prostatectomy | NCT01220427a |
| Blood and Tissue Samples From Patients with Locally Recurrent or Metastatic Prostate Cancer | Sequencing of genomic tumor DNA, genotyping, gene expression, and miRNA/noncoding RNA | Observational prospective | Blood, soft tissue or bone metastases | NCT01050504a |
| MicroRNA in Prostate Cancer Progression: Genetic Variation, Genotype-Phenotype Correlation, and Circulating Biomarker | MiRNAs as predictors of progression | Biomarker screening | Tumor versus normal tissue, plasma | MD Anderson Cancer Centerb |
| Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer | MiRNA expression in tumor metastases as biomarker for sensitivity and resistance; correlation of miRNA with response and progression | Interventional, Phase II clinical trial | Blood (biopsy) | NCT01503229a |
| Bicalutamide and Goserelin or Leuprolide Acetate w/wo Cixutumumab in Patients with Newly Diagnosed Metastatic Prostate Cancer | Correlation of miRNA expression and CTC count | Interventional, Phase II clinical trial | Serum | NCT01120236a |

ahttp://clinicaltrials.gov.
bhttp://www.mdanderson.org.

exclusively present in exosomes [96]. In larger extracellular vesicles (>200 nm), miR-141, miR-375, and miR-205, known to be associated with PCa progression, and miR-31 (which targets AR) were differentially expressed [97]. So far, there are only few reports analyzing miRNAs in microvesicles derived from PCa patients. However, a recent study found differential expression of eleven miRNAs, of which miR-107 exhibited the largest differential expression in circulating microvesicles from PCa patients compared to controls [86]. Additionally, 16 miRNAs were found to be enriched in microvesicles of patients with metastatic PCa compared to patients with organ-confined disease [86]. In this study, miR-375 and miR-141 were significantly enriched in plasma-derived microvesicles from patients with metastatic disease. Exosomal Tmprss2:ErG and Pca3 mRNA from urine samples of untreated PCa patients have also been proposed as a potential diagnostic test [98].

All exosomal content is derived from their parental cells. However, the precise mechanism of miRNA/LncRNA/protein delivery into exosomes is not fully understood. Notably, the RNA and protein cargo within exosomes was shown to be functionally active in recipient cells, which suggests that tumor cells can exploit circulating exosomes as a means to “communicate” with their regional or distal environment [95, 99, 100].

5. Preclinical Studies for ncRNA-Based PCa Therapy

With the identification of PCa-specific miRNA expression patterns and the understanding of their role in PCa biology, novel opportunities for miRNA-based therapies arise. These include targeting the 3’UTRs of oncogenes using specific miRNAs, restoring normal intracellular miRNA pools, or enhancing therapeutic response by combining miRNA with existing anticancer drugs, attempting to exploit the concept of synthetic lethality. In this section, we highlight in vivo studies that support the implementation of miRNA-based therapeutics (Table 3).

The ability of let-7 to inhibit tumor initiation was first demonstrated in a murine CD44-positive xenograft model, where overexpression and therapeutic injection of let-7 resulted in delayed tumor formation [101–103]. Intratumoral administration of miR-199a-3p mimics into a murine PCa xenograft model led to decreased expression of the onco-gene Aurora kinase A (Aurka), which is associated with a malignant PCa phenotype [104]. In another murine xenograft model, using transfected PCa cell lines [103], miR-128 showed antiproliferative as well as proapoptotic effects and negatively regulated PCa stem cells by directly targeting the stem cell related genes Bmi-1 and Nanog (Nanog homeobox). Additionally, clonogenic and tumorigenic properties of PCa cells were inhibited in a dose-dependent manner by different levels of endogenous miR-128. MiR-16 replacement therapy in a luciferase PCa xenograft substantially reduced bone metastatic tumor growth compared to untreated mice [105]. MiR-26a, which is downregulated in PCa, was shown to inhibit growth and metastatic progression of human-tumor xenografts, probably by targeting lin-28 homolog B (Lin28B) and zinc finger CCHC domain containing II (Zcchc11) [106]. Finally, downregulation of the LncRNA Malat-1
delayed tumor growth in vivo and reduced metastasis of PCa xenografts in castrated male nude mice [62]. Intratumoral and systemic injection of miR-34a into mice grafted with human PCa tumors resulted in reduced tumor volumes and lung metastasis and was associated with prolonged survival by suppressing the adhesion molecule CD44 [107]. Deregulated miR-34a expression was also linked to drug resistance, showing a sevenfold decrease in paclitaxel-resistant PC-3 cells compared to wild-type PC-3 cells [108]. Overexpression of miR-34a in paclitaxel-resistant PC-3 cells recovered paclitaxel sensitivity, while miR-34a antagonim transection attenuated it [108].

Liuet al. [107] and Kojima et al. [108] presented a rationale for miR-34a-based therapy to target PCa stem cells and drug-resistant PCa. MiR-34a has emerged as therapeutic agent under the name MRX34, a liposome-encapsulated miR-34 mimic (http://www.mirnatherapeutics.com) and is currently being studied in a multicenter Phase I clinical trial in patients with unresectable primary liver cancer and liver metastases derived from tumors of other primary origin (NCT01829971; https://clinicaltrials.gov/).

Restoration of miR-30b expression by src tyrosine kinase (Src) inhibitors was able to prolong survival and reduce metastatic disease of VCaP-derived xenograft mouse by negatively regulating TMPRSS2:ERG and downregulating EMT-associated as well as ERG target genes [109]. Consequently, inhibitors of the AR activator Src are currently being tested in Phase I and II clinical trials for the treatment of PCa patients. Similar to the reconstitution of silenced miRNAs, suppression of overexpressed miRNAs was also shown to be a potential therapeutic approach: Mercatelli et al. established an antagonim targeting miR-221 [110]. Inverse correlation of miR-221 and p27 protein level was validated in primary cells from 18 patients with stage II-III PCa. In mouse xenograft models, intratumoral injection of a miR-221 antagonim led to significantly reduced tumor growth, which was correlated with p27 upregulation [110].

There are currently no clinical trials studying miRNAs as therapeutics in human PCa. However, the data from these and other preclinical in vivo models using miRNA-based therapeutic approaches provide promising results for potential future applications in human PCa.

### 6. Summary

The advent of ultra-high throughput sequencing technologies has caused a vast expansion of the catalog of noncoding RNA molecules. Thus, on the one hand, we are closer to an overview of the transcriptional landscapes in health and disease. On the other hand, the complexity of regulatory factors has grown substantially, and we have just started to uncover some underlying principles: although miRNAs are probably the best investigated class of noncoding RNAs, the recent discoveries of complex miRNA and ceRNA networks and nuclear miRNAs indicate that our understanding of miRNAs in PCa progression is far from complete. Similarly, the analysis of IncRNAs has just commenced, and the roles of the majority of PCATs and other IncRNAs in PCa remain to be investigated. The reports on novel diagnostic PCa biomarkers from liquid biopsies are encouraging. However, the data are mostly based on discovery-driven approaches that frequently have limited validity due to small sample sizes, nonstandardized settings, and different experimental designs. Thus, the diagnostic and therapeutic benefits of many potential RNA markers in PCa still need to be proven in well-controlled and standardized large-scale prospective clinical studies.

### Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| BPH | Benign prostate hyperplasia |
| ceRNA | Competitive endogenous RNA |
| CHART | Capture analysis of RNA targets |
| ChIP | Chromatin immunoprecipitation |
| ChIRP | Chromatin isolation with RNA purification |
| circRNA | Circular RNA |
| CLASH | Crosslinking, ligation, and sequencing of hybrids |
| CRPC | Castration-resistant prostate cancer |
| DHT | Dihydrotestosterone |
| EMT | Epithelial-to-mesenchymal transition |
| HITS-CLIP | High throughput sequencing of RNA isolated by UV crosslinking immunoprecipitation |

| miRNA | Target | Model used | Delivery method | Phenotypes | Reference |
|-------|--------|------------|-----------------|-------------|-----------|
| Let-7 | Myc, RAS | AR-negative mouse xenograft | Let-7c-lentivirus intratumoral injection | Repressed tumor growth | Nadiminty et al. [102] |
| miR-199a-3p | Aurora kinase A | DU145 mouse xenograft | Agomir intratumoral injection | Reduced tumor growth | Qu et al. [104] |
| miR-16 | CDK1, CDK2 | Murine bone metastatic prostate cancer model | Intravenous injections | Reduced tumor development in bone tissue | Takeshita et al. [105] |
| miR-34a | CD44, SIRT1 | CD44+ mouse xenograft | Intratumoral and systemic injection of miR-34a oligo | Reduced tumor volume and lung metastasis, prolonged survival | Liu et al. [107] |
| miR-221 | p27 | PC-3 mouse xenograft | Intratumoral injections of miR-221/miR-222 antagonim | Reduced tumor growth | Mercatelli et al. [110] |
lncRNAs: Long intergenic noncoding RNAs
lncRNA: Long noncoding RNA
miRNA: microRNAs
PAR-CLIP: Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation
PCA: Prostate cancer
PCAT: Prostate cancer associated transcript (nonprotein coding)
piRNA: piwi-interacting RNA
PRC2: Polycomb repressive complex 2
PSA: Prostate-specific antigen
RIP-Seq: RNA immunoprecipitation sequencing
RISC: RNA-induced silencing complex.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution
Julia M. A. Pickl and Doreen Heckmann contributed equally to this work.

Acknowledgments
This work was supported by the German Federal Ministry of Education and Science in the framework of the Program for Medical Genome Research (FKZ 01KI01001A), the Bruno und Helene Jöster Stiftung, and the German Cancer Consortium (DKTK).

References
[1] G. K. Wong, D. A. Passey, and J. Yu, "Most of the human genome is transcribed," Genome Research, vol. 11, no. 12, pp. 1975–1977, 2001.
[2] P. Kapranov, S. E. Cawley, J. Drenkow et al., "Large-scale transcriptional activity in chromosomes 21 and 22," Science, vol. 296, no. 5569, pp. 916–919, 2002.
[3] P. Bertone, V. Stolc, T. E. Royce et al., "Global identification of human transcribed sequences with genome tiling arrays," Science, vol. 306, no. 5675, pp. 2242–2246, 2004.
[4] S. Djebali, C. A. Davis, A. Merkel et al., "Landscape of transcription in human cells," Nature, vol. 489, no. 7414, pp. 101–108, 2012.
[5] T. Derrien, R. Johnson, G. Bussotti et al., "The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression," Genome Research, vol. 22, no. 9, pp. 1775–1789, 2012.
[6] J. Lu, G. Getz, E. A. Miska et al., "MicroRNA expression profiles classify human cancers," Nature, vol. 435, no. 7043, pp. 834–838, 2005.
[7] Z. Du, T. Fei, R. G. W. Verhaak et al., "Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer," Nature Structural and Molecular Biology, vol. 20, no. 7, pp. 908–913, 2013.
[8] S. Djuranovic, A. Nahvi, and R. Green, "miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay," Science, vol. 336, no. 6078, pp. 237–240, 2012.
[9] H. Guo, N. T. Ingolia, J. S. Weissman, and D. P. Bartel, "Mammalian microRNAs predominantly act to decrease target mRNA levels," Nature, vol. 466, no. 7308, pp. 835–840, 2010.
[10] J. E. Braun, E. Huntzinger, M. Fauser, and E. Izaurrealde, "GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA targets," Molecular Cell, vol. 44, no. 1, pp. 120–133, 2011.
[11] D. P. Bartel, "MicroRNAs: target recognition and regulatory functions," Cell, vol. 136, no. 2, pp. 215–233, 2009.
[12] S. Wach, E. Nolte, J. Szczyrba et al., "MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening," International Journal of Cancer, vol. 130, no. 3, pp. 611–621, 2012.
[13] J. Szczyrba, E. Löprich, S. Wach et al., "The microRNA profile of prostate carcinoma obtained by deep sequencing," Molecular Cancer Research, vol. 8, no. 4, pp. 529–538, 2010.
[14] A. W. Tong, P. Fulgham, C. Jay et al., "MicroRNA profile analysis of human prostate cancers," Cancer Gene Therapy, vol. 16, no. 3, pp. 206–216, 2009.
[15] J. C. Brase, M. Johannes, T. Schlomme et al., "Circulating miRNAs are correlated with tumor progression in prostate cancer," International Journal of Cancer, vol. 128, no. 3, pp. 608–616, 2011.
[16] M. Hart, E. Nolte, S. Wach et al., "Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing," Molecular Cancer Research, vol. 12, no. 2, pp. 250–263, 2014.
[17] A. Schaefer, M. Jung, H. Mollenkopf et al., "Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma," International Journal of Cancer, vol. 126, no. 5, pp. 1166–1176, 2010.
[18] K. Tsuchiyama, H. Ito, M. Taga et al., "Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer," Prostate, vol. 73, no. 8, pp. 827–834, 2013.
[19] J. Szczyrba, E. Nolte, S. Wach et al., "Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma," Molecular Cancer Research, vol. 9, no. 6, pp. 791–800, 2011.
[20] M. R. Lang, L. A. Lapierre, M. Frotscher, J. R. Goldenring, and E. W. Knapik, "Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation," Nature Genetics, vol. 38, no. 10, pp. 1198–1203, 2006.
[21] J. Xiao, A. Gong, A. N. Eischeid et al., "MiR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein," Prostate, vol. 72, no. 14, pp. 1514–1522, 2012.
[22] S. Wei, T. A. Dunn, W. B. Isaacs, A. M. de Marzo, and J. Luo, "GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus," Prostate, vol. 68, no. 13, pp. 1387–1395, 2008.
[23] T. A. Dunn, S. Chen, D. A. Faith et al., "A novel role of myosin VI in human prostate cancer," The American Journal of Pathology, vol. 169, no. 5, pp. 1843–1854, 2006.
[24] Q. Cao, R. Mani, B. Ateeq et al., "Coordinated regulation of polycomb group complexes through microRNAs in cancer," Cancer Cell, vol. 20, no. 2, pp. 187–199, 2011.
[25] L. V. Williams, D. Veliceasa, E. Vinokour, and O. V. Volpert, "miR-200b inhibits prostate cancer EMT, growth and metastasis," PLoS ONE, vol. 8, no. 12, Article ID e83991, 2013.
[26] P. A. Gregory, A. G. Bert, E. L. Paterson et al., “The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIPI,” *Nature Cell Biology*, vol. 10, no. 5, pp. 593–601, 2008.

[27] Y.-. Liu, J. J. Yin, W. Abou-Kheir et al., “MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms,” *Oncogene*, vol. 32, no. 3, pp. 296–306, 2013.

[28] M. B. Stope, C. Stender, T. Schubert et al., “Heat-shock protein HSPBI attenuates microRNA miR-1 expression thereby restoring oncogenic pathways in prostate cancer cells,” *Anticanccer Research*, vol. 34, no. 7, pp. 3475–3480, 2014.

[29] S. Majid, A. A. Dar, S. Saini et al., “miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways,” *Clinical Cancer Research*, vol. 19, no. 1, pp. 73–84, 2013.

[30] S. C. Theodore, M. Davis, F. Zhao et al., “MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltransferase 1,” *Oncotarget*, vol. 5, no. 11, pp. 3512–3525, 2014.

[31] S. Varambally, J. Yu, B. Laxman et al., “Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression,” *Cancer Cell*, vol. 8, no. 5, pp. 393–406, 2005.

[32] L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman, and P. P. Pandolfi, “A coding-independent function of gene and pseudogene mRNAs regulates tumour biology,” *Nature*, vol. 465, no. 7301, pp. 1033–1038, 2010.

[33] J. Schug, L. B. McKenna, G. Walton et al., “Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver,” *BMC Genomics*, vol. 14, no. 1, article 264, 2013.

[34] G. B. Loeb, A. A. Khan, D. Canner et al., “Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting,” *Molecular Cell*, vol. 48, no. 5, pp. 760–770, 2012.

[35] M. Hafner, M. Landthaler, L. Burger et al., “Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP,” *Cell*, vol. 141, no. 1, pp. 129–141, 2010.

[36] A. Helwak, G. Kudla, T. Dudnakova, and D. Tollervey, “Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding,” *Cell*, vol. 153, no. 3, pp. 654–665, 2013.

[37] R. Tang, L. Li, D. Zhu et al., “Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system,” *Cell Research*, vol. 22, no. 3, pp. 504–515, 2012.

[38] S. A. Khudayberdiev, F. Zampa, M. Rajman, and G. Schratt, “A comprehensive characterization of the nuclear microRNA repertoire of post-mitotic neurons,” *Frontiers in Molecular Neuroscience*, vol. 6, article 43, 2013.

[39] V. Huang, J. Zheng, Z. Qi et al., “Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells,” *PLoS Genetics*, vol. 9, no. 9, Article ID e1003821, 2013.

[40] J. Liao, L. Ma, Y. Guo et al., “Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of mirnas and tRNA 3′ trailers,” *PLoS ONE*, vol. 5, no. 5, Article ID e00563, 2010.

[41] M. Salmanidis, K. Pillman, G. Goodall, and C. Bracken, “Direct transcriptional regulation by nuclear microRNAs,” *International Journal of Biochemistry & Cell Biology*, vol. 2014.
detection in blood and tissue samples for prostate cancer diagnosis," *Clinical Chemistry and Laboratory Medicine*, vol. 51, no. 4, pp. 881–887, 2013.

[93] S. A. Tomlins, S. M. J. Aubin, J. Siddiqui et al., “Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA,” *Science Translational Medicine*, vol. 3, no. 94, Article ID 94ra72, 2011.

[94] D. Cao, D. Ye, H. Zhang, Y. Zhu, Y. Wang, and X. Yao, “A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer,” *Prostate*, vol. 71, no. 7, pp. 700–710, 2011.

[95] M. Mittelbrunn, C. Gutiérrez-Vázquez, C. Villarroya-Beltrí et al., “Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells,” *Nature Communications*, vol. 2, no. 1, article 282, 2011.

[96] N. P. Hessvik, S. Phuyal, A. Brech, K. Sandvig, and A. Llorente, “Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells,” *Biochimica et Biophysica Acta*, vol. 1819, no. 11-12, pp. 1154–1163, 2012.

[97] M. Morello, V. R. Minciacchi, P. de Candia et al., “Large oncosomes mediate intercellular transfer of functional microRNA,” *Cell Cycle*, vol. 12, no. 22, pp. 3526–3536, 2013.

[98] J. Nilsson, J. Skog, A. Nordstrand et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer,” *British Journal of Cancer*, vol. 100, no. 10, pp. 1603–1607, 2009.

[99] K. Gabriel, A. Ingram, R. Austin et al., “Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer,” *PLoS ONE*, vol. 8, no. 7, Article ID e70047, 2013.

[100] J. C. Gross, V. Chaudhary, K. Bartscherer, and M. Boutros, “Active Wnt proteins are secreted on exosomes,” *Nature Cell Biology*, vol. 14, no. 10, pp. 1036–1045, 2012.

[101] C. Liu, K. Kelnar, A. V. Vlassov, D. Brown, J. Wang, and D. G. Tang, “Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7,” *Cancer Research*, vol. 72, no. 13, pp. 3393–3405, 2012.

[102] N. Nadiminty, R. Tummala, W. Lou et al., “MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth,” *PLoS ONE*, vol. 7, no. 3, Article ID e32832, 2012.

[103] M. Jin, T. Zhang, and C. Liu, “miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells,” *Cancer Research*, vol. 74, no. 15, pp. 4183–4195, 2014.

[104] Y. Qu, X. Huang, Z. Li et al., “miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment,” *The American Journal of Pathology*, vol. 184, no. 5, pp. 1541–1549, 2014.

[105] F. Takeshita, L. Patrawala, M. Osaki et al., “Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes,” *Molecular Therapy*, vol. 18, no. 1, pp. 181–187, 2010.

[106] X. Fu, Z. Meng, W. Liang et al., “miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis,” *Oncogene*, 2013.

[107] C. Liu, K. Kelnar, B. Liu et al., “The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,” *Nature Medicine*, vol. 17, no. 2, pp. 211–216, 2011.

[108] K. Kojima, Y. Fujita, Y. Nozawa, T. Deguchi, and M. Ito, “MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms,” *Prostate*, vol. 70, no. 14, pp. 1501–1512, 2010.